Delivery Order SPE2DB24D2010-SPE2DB25FABCB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a contract ceiling value of $1,773.46. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 26, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) at a ceiling value of $1,665.22. This firm fixed-price delivery order, with an ultimate completion date of August 19, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,143.98. The delivery order, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competitive award to the prime contractor. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 50 mg capsules (100 count units) with a ceiling value of $1,441.35. This is a firm fixed price delivery order with an ultimate completion date of September 2, 2025, and represents a non-competitive, non-set-aside award. The contract is performed from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,609.67 to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100 count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price delivery order, issued with no set-aside designation, is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under AmerisourceBergen's broader contracting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a contract ceiling value of $3,982.75. This is a firm fixed price delivery order with no set-aside designation, issued competitively under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a ceiling value of $1,231.76. This is a firm fixed-price delivery order with an ultimate completion date of August 28, 2025, and no set-aside designation was applied. The award represents a competitive procurement executed under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a contract value of $5,729.56. This is a firm fixed price delivery order with an ultimate completion date of August 28, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FABCBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,680.85 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100-count units) on September 8, 2025, with an ultimate completion date of September 9, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle, designated SPE2DX, serves as a comprehensive global pharmaceutical support mechanism enabling the company to supply a wide range of medications, vaccines, and medical supplies to military healthcare programs and other federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. Vyvanse, a prescription stimulant medication, represents one of the many pharmaceutical products AmerisourceBergen supplies to support federal medical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/8/25 |